PharmExec Blog

Actavis Marches Ahead with Acquisition Spree

Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 — a “dramatic elevation”, given the $8.7 billion revenues it recorded in 2013, reports research and consulting firm GlobalData. Read More »

Posted in Deals | Tagged , , , | Leave a comment

CMS Struggles to Fix Sunshine System

The feds have “a long way to go” to get the Open Payments system operating effectively and user friendly, according to officials in charge of the financial disclosure program. “Sunshine” went live September 30, 2014, as scheduled, but incomplete and contradictory data listings made it necessary to withhold nearly one-third of financial transaction reports from pharma and medical device companies.

“This was our first shot at getting the data out there,” acknowledged Doug Brown, acting director of the Data Sharing & Partnership Group at the Center for Program Integrity, which runs the Open Payments program for the HHS Centers for Medicare and Medicaid Services (CMS). Read More »

Posted in FDA, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment

No-One's in Charge of Pharmaceuticals in Europe!

Peter O’Donnell’s recent Applied Clinical Trials blog, ‘Who’s in charge of Medicines in Brussels?‘, has been overtaken by history, with the departure of Guido Rasi from his post of Executive Director of the European Medicines Agency.

At a time of flux in the European context for pharmaceuticals, Rasi’s moderate manner and capacity for strategic thinking were one reassurance amid so much uncertainty, writes Peter, and his removal is to be lamented.

Click here for more.

Posted in Europe, Regulatory | Tagged , , | Leave a comment

EMA States Position on Confidential Information

In response to a letter the European Medicines Agency received from the European Ombudsman on Oct. 27, 2014, the agency is clarifying its policy on commercially confidential information. EMA states in its response that the agency is responsible for ruling on redactions of published documents and bases its decisions in accordance with laws and internal rules. Read More »

Posted in Europe | Tagged , , | Leave a comment

J&J Strengthens Infectious Disease Pipeline with Alios Acquisition

Johnson & Johnson completed the acquisition of Alios BioPharma, a privately held clinical-stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash. Alios BioPharma will become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.

The acquisition includes Alios BioPharma’s portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy currently in Phase II studies for the treatment of infants with respiratory syncytial virus (RSV). RSV is the last of the major pediatric diseases that currently has no effective therapy. The acquisition also includes two early-stage compounds for hepatitis C (HCV) that could potentially augment Janssen’s existing HCV portfolio.

Source: Johnson & Johnson

Posted in Deals | Tagged , , , | Leave a comment
  • Categories

  • Meta